A B S T R A C T Oxidation of the side chain of 5,3-cholestane-3a,7a,12a-triol was studied in a patient with cerebrotendinous xanthomatosis (CTX) and in control subjects, using various subcellular fractions of liver homogenate and a method based on isotope dilution-mass spectrometry.In the control, 5p8-cholestane-3a,7a,12a-triol was converted into 5f3-cholestane-3a,7a,12a,26-tetrol and 3a,7a,12a-trihydroxy-5,8-cholestanoic acid by the mitochondrial fraction, and into 5,8-cholestane-3a,7a,12a,-25-tetrol by the microsomal fraction.In the CTX patient, liver mitochondria were completely devoid of 26-hydroxylase activity. The same mitochondrial fraction catalyzed 25-hydroxylation of vitamin D3.The microsomal fraction of liver of the subject with CTX contained more than 50-fold the normal amount of 5f3-cholestane-3a,7a,12a-triol.The basic metabolic defect in CTX appears to be a lack of the mitochondrial 26-hydroxylase. The excretion in the bile of 5,p-cholestane-3a,7a,12a,25-tetrol and 5f3-cholestane-3a,7a,12a,24a,25-pentol observed in CTX patients may be secondary to the accumulation of the major substrate for the 26-hydroxylase, i.e., 5,8-cholestane-3a,7a,12a-triol, and exposure of this substrate to the normally less active microsomal 25-and 24-hydroxylases. It is concluded that the major pathway in the biosynthesis of cholic acid in human liver involves a mitochondrial C27-steroid 26-hydroxylation.